Nanjing/Suzhou, Late August 2026 — Yang Sheng, deputy commissioner of China’s National Medical Products Administration (NMPA), led a delegation to Jiangsu Province to survey innovative drug companies in Nanjing and Suzhou, signaling top-level regulatory support for the province’s biologics and chemical innovation pipeline as Beijing doubles down on whole-chain policies to advance the pharmaceutical sector.
Policy Snapshot
| Attribute | Detail |
|---|---|
| Official | Yang Sheng, NMPA Deputy Commissioner |
| Location | Nanjing and Suzhou, Jiangsu Province |
| Participants | NMPA Drug Registration Department; Jiangsu Provincial Medical Products Administration |
| Focus areas | Biologics; chemical innovative drugs; frontier R&D projects |
| Key themes | Whole-chain support; regulatory reform; central-local coordination |
Key Messages
Yang praised Jiangsu’s achievements in innovative drug development and emphasized that the central party and State Council prioritize biomedical industry growth, with comprehensive policies backing the entire innovation chain. He urged stakeholders to seize development opportunities, concentrate on frontier fields and key technologies, pioneer new tracks and models, accelerate breakthrough product development, and cultivate original first-in-class drugs with high clinical value and strong international competitiveness.
The NMPA will continue deepening evaluation and approval system reforms, optimize central-local coordination mechanisms, enhance regulatory service quality and efficiency, and intensify support for innovative drug R&D to propel high-quality development of the biomedical industry.
Market Impact Analysis
The high-level NMPA visit to Jiangsu—one of China’s densest clusters of biotech and pharmaceutical innovation—sends a strong signal to investors and developers that regulatory capital will continue flowing toward cutting-edge drug modalities. By explicitly calling for “original first-in-class” products with global competitiveness, Yang is elevating the innovation bar beyond fast-follower generics and biosimilars, aligning with Beijing’s strategic goal to reduce dependence on imported novel therapies.
The emphasis on “whole-chain support” and “central-local coordination” suggests forthcoming regulatory refinements that could streamline clinical trial approvals, accelerate priority review pathways, and harmonize provincial-level implementation of national biotech policies. For Jiangsu-based firms, proximity to regulators and demonstrated central government attention may translate into faster feedback loops during the registration process and preferential access to pilot programs for breakthrough therapies.
Forward-Looking Statement
Industry analysts expect the NMPA to unveil concrete measures to optimize the central-local coordination model by year-end, potentially including delegated review authority for mature provincial regulators like Jiangsu and expanded rolling submission pathways for innovative biologics. The focus on “new tracks and models” hints at regulatory sandbox opportunities for cell and gene therapies, radiopharmaceuticals, and AI-enabled drug development platforms. Companies with frontier pipelines in Nanjing and Suzhou are likely to benefit from intensified policy tailwinds, though the call for “internationally competitive” original drugs implies that only assets with global trial footprints and differentiated mechanisms will capture sustained regulatory support.-China Health Reform Pulse
Policy Source: https://www.nmpa.gov.cn/yaowen/ypjgyw/ypyw/20260828090800151.html